BeOne Medicines (NASDAQ:ONC) Price Target Raised to $463.00

BeOne Medicines (NASDAQ:ONC) had its target price boosted by equities research analysts at Citizens Jmp from $405.00 to $463.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage currently has a “market outperform” rating on the stock. Citizens Jmp‘s price objective points to a potential upside of 14.36% from the stock’s previous close.

Several other equities research analysts have also recently commented on the stock. JPMorgan Chase & Co. boosted their price target on shares of BeOne Medicines from $425.00 to $445.00 and gave the stock an “overweight” rating in a research report on Thursday, October 1st. Jefferies Financial Group restated a “buy” rating and issued a $470.00 price objective on shares of BeOne Medicines in a report on Thursday. Weiss Ratings upgraded BeOne Medicines from a “hold (c+)” rating to a “buy (b-)” rating in a report on Thursday, October 8th. Guggenheim lifted their target price on BeOne Medicines from $420.00 to $430.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Finally, Barclays upped their target price on BeOne Medicines from $407.00 to $415.00 and gave the stock an “overweight” rating in a report on Thursday, September 10th. Sixteen equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $430.46.

BeOne Medicines Stock Up 4.5%

Shares of NASDAQ ONC traded up $17.62 during midday trading on Friday, reaching $404.87. The company’s stock had a trading volume of 351,349 shares, compared to its average volume of 316,822. The company has a current ratio of 3.40, a quick ratio of 3.06 and a debt-to-equity ratio of 0.17. BeOne Medicines has a fifty-two week low of $253.95 and a fifty-two week high of $409.80. The stock has a market capitalization of $44.45 billion, a price-to-earnings ratio of 71.06 and a beta of 0.63. The stock has a 50 day simple moving average of $362.80 and a 200-day simple moving average of $325.98.

BeOne Medicines (NASDAQ:ONC) last announced its earnings results on Thursday, November 5th. The company reported $3.64 EPS for the quarter, topping the consensus estimate of $2.34 by $1.30. The business had revenue of $1.89 billion during the quarter, compared to analysts’ expectations of $1.76 billion. BeOne Medicines had a net margin of 10.70% and a return on equity of 14.23%. Equities research analysts predict that BeOne Medicines will post 8.99 earnings per share for the current year.

Insider Activity

In related news, SVP Chan Lee sold 2,666 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $360.00, for a total value of $959,760.00. Following the completion of the sale, the senior vice president directly owned 812 shares in the company, valued at approximately $292,320. This trade represents a 76.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John Oyler sold 115,011 shares of BeOne Medicines stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $357.87, for a total value of $41,158,986.57. Following the transaction, the chief executive officer owned 125,799 shares of the company’s stock, valued at $45,019,688.13. The trade was a 47.76% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 376,373 shares of company stock valued at $134,848,154 in the last ninety days. Corporate insiders own 6.19% of the company’s stock.

Institutional Investors Weigh In On BeOne Medicines

Hedge funds have recently added to or reduced their stakes in the business. Mather Group LLC. boosted its holdings in shares of BeOne Medicines by 192.0% during the third quarter. Mather Group LLC. now owns 73 shares of the company’s stock worth $27,000 after acquiring an additional 48 shares during the period. GAMMA Investing LLC increased its position in shares of BeOne Medicines by 39.5% in the third quarter. GAMMA Investing LLC now owns 120 shares of the company’s stock worth $44,000 after purchasing an additional 34 shares during the period. Knights of Columbus Asset Advisors LLC acquired a new position in shares of BeOne Medicines in the 3rd quarter valued at approximately $106,000. Provenance Wealth Advisors LLC acquired a new stake in shares of BeOne Medicines in the 3rd quarter valued at $106,000. Finally, Parallel Advisors LLC boosted its stake in BeOne Medicines by 24.0% in the first quarter. Parallel Advisors LLC now owns 351 shares of the company’s stock valued at $104,000 after buying an additional 68 shares in the last quarter. Institutional investors and hedge funds own 48.55% of the company’s stock.

Key BeOne Medicines News

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: BeOne reported third-quarter EPS of $3.64, topping the $2.34 consensus estimate, while revenue of $1.89 billion exceeded expectations of $1.76 billion. The company also raised its 2026 revenue guidance, adding to the positive outlook. BeOne Medicines Q3 Adjusted Earnings, Revenue Rise; 2026 Revenue Guidance Raised
• Positive Sentiment: The FDA granted priority review to a BRUKINSA combination for first-line mantle cell lymphoma. The review could bring a decision on the potential label expansion sooner, creating an opportunity to broaden the treatment’s use if approved. FDA Priority Review for BRUKINSA Combination

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company focused on discovering, developing, manufacturing and commercializing medicines for cancer patients. Formerly known as BeiGene, the company operates an integrated biotechnology platform spanning research, clinical development, regulatory activities and commercial operations.

Its portfolio includes BRUKINSA (zanubrutinib), a Bruton’s tyrosine kinase inhibitor used in the treatment of several blood cancers, and TEVIMBRA (tislelizumab), an anti-PD-1 immunotherapy approved in multiple markets for certain cancers.